Guangzhou Lupeng Pharmaceutical Company LTD.
17
9
12
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.4% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Role: lead
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Role: lead
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Role: lead
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Role: lead
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Role: lead
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Role: lead
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Role: lead
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
Role: lead
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Role: lead
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Role: lead
A Study of LP-118 in Patients With Advanced Tumors
Role: lead
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Role: lead
A Study of LP-128 Capsules in Healthy Subjects
Role: lead
The Mass Balance Study of LP-168 in Healthy Subjects
Role: lead
A Food Effect Study of LP-168 Tablets in Healthy Subjects
Role: lead
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
Role: collaborator
A Study of LP-168 in Healthy Volunteers
Role: lead
All 17 trials loaded